drugset / Trial / NCT00307502
Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
Phase 1
Completed
675 enrolled
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the influence of the individual characteristics on the pharmacokinetic parameters in the Spanish population of HIV-infected subjects.
Timeline
- Start
- 2005-01
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 150 mg | — |
| Subject | Atazanavir | Other / unclassified | 200 mg | — |
| Subject | Darunavir | Small molecule | 300 mg | — |
| Subject | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | Fosamprenavir | Small molecule | 700 mg | — |
| Subject | INDINAVIR ANHYDROUS | Other / unclassified | 400 mg | — |
| Subject | Lopinavir | Other / unclassified | 200 mg | — |
| Subject | Nelfinavir | Other / unclassified | 250 mg | — |
| Subject | Nevirapine | Small molecule | 200 mg | — |
| Subject | Ritonavir | Other / unclassified | 50 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | Saquinavir | Small molecule | 500 mg | — |
| Subject | Tipranavir | Small molecule | 250 mg | — |